A venture capital firm based in Europe with an additional office in New York manages €176 million in total assets across two funds. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€8million ($0.7million-$10million). The current fund aims to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture / life science investment arm of a life science and medical equipment manufacturer invests from an evergreen fund. The firm prefers to invest at company formation / seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record, but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with regulatory affairs, market access and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A transatlantic investment fund based in the Netherlands manages four healthcare technology funds. The firm focuses on investing in companies developing therapeutics, medical devices, diagnostics and digital health. The firm prefer to invest in clinical stage therapeutics companies and commercial stage diagnostics/medical technology companies. The investment size ranges from €5 million up to €30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm primarily invests in Europe-based diagnostic companies, and US-based medical device, diagnostics and digital health companies.

The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational pharmaceutical company headquartered in Japan with a US subsidiary division is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets.

The firm’s external R&D is focused on both neurodegerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is also interested in diabetes, immunology, and infectious diseases. The firm is seeking platform technology with new MOA such as gene therapy, stem cell therapy, and monoclonal antibody acting on new targets. The firm prefers early stage, pre-POC assets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Michigan, USA is investing exclusively in early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities.

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP.

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm backed by a China-based investment group was founded in 2017 and is based in San Francisco, CA. The firm closed its inaugural fund of $300M and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest $15-20M over the life of the company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest mainly in USA-based companies but may invest up to 20% of the fund in companies based in Western Europe.

The firm is focused solely on early-stage therapeutics and will not consider opportunities in medical devices, diagnostics, healthcare services or healthcare IT. The firm is primarily interested in traditional therapeutic modalities – programs that aim to discover and develop small molecule, antibody/protein-based clinical candidates will be considered. The ideal stages of development would be anywhere from IND candidate (12-24 months from the clinic) through Phase I, and the firm is open to all indications including orphan and rare diseases.

The firm can work with all types of management teams and places more importance on their technology. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A leading global insurance company based in the UK launched a corporate venture capital arm in 2015. The fund will invest £100M over the next 3-5 years and will generally allocate £1-5M for up to 20% equity stake, and selectively does convertible financing as well. The firm does not invest strictly for financial returns and seeks a strategic relationship with the companies they invest in. The firm will typically participate in Series A and B rounds. The firm anticipates 4-5 investments per year, although this number is subject to fluctuate depending on deal flow. The firm will invest in technologies that will impact regions where the parent company has a footprint.

In the life sciences space, the firm seeks innovative technologies that can disrupt and transform the future of insurance. The firm will not consider therapeutics or biopharma opportunities. Any technology with implications to the insurance industry will be considered, including smart diagnostics, genomics, etc. The firm has expressed interest in technology that helps with chronic disease management and considered telemedicine companies as well. In terms of diagnostics, the firm expects the technology to be undergoing promising clinical trials that contribute to its validation. For companies that fall into the healthcare IT sector, the firm expects some ongoing traction and key partnerships to be in place.

The firm seeks to work with companies backed by a full management team with strong industry expertise. Ideally, the team will have a strong life sciences background and an experienced advisory team, with good understanding of how their product or technology works. The firm can act as the lead or co-investor and will most likely take a board seat if they were to lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com